The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...

Ketamine therapy has become known for its effects at combating depression and other mood disorders. There’s a growing body of ...

The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the ...

The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...

FDA approves esketamine nasal spray as a standalone treatment for adults with treatment-resistant depression, offering rapid ...

The results, which come on the heels of the FDA’s approval of J&J’s esketamine nasal spray Spravato as a monotherapy for ...

A ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression ...

Atai Life Sciences N.V. reported positive top-line phase 2a results of BPL-003 in treating Alcohol Use Disorder patients.

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

A nasal spray therapy for treatment-resistant major depressive disorder (MDD) has now been approved by the Food and Drug ...